Welcome to our dedicated page for Cosmos Health SEC filings (Ticker: COSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cosmos Health Inc. filings document the public-company record of a Nevada healthcare issuer with common stock listed on the Nasdaq Capital Market under COSM. Recent Form 8-K reports cover operating results, Regulation FD disclosures, Nasdaq minimum-bid-price compliance matters, board appointments, annual-meeting voting results and capital-structure proposals involving common stock and blank-check preferred stock.
The filing record also includes a Form 12b-25 notice for a delayed annual report and disclosures tied to business performance across contract manufacturing, wholesale distribution, proprietary nutraceutical brands and research and development. These documents address governance, listing status, share authorization, financial reporting timing and the company's operating subsidiaries and product portfolio.
Cosmos Health Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held on July 15, 2026 at 9:00 A.M. (Central Time) at its U.S. headquarters in Chicago. The Board asks shareholders of record as of May 19, 2026 to vote on four proposals: (1) elect six directors, (2) ratify the independent auditor, (3) approve a 2026 equity incentive plan, and (4) approve designation and issuance of Series B Preferred Stock. The Board unanimously recommends a vote FOR each proposal. Shares outstanding were 59,956,994 as of the Record Date.
The proxy materials and the 2025 Annual Report on Form 10-K are available at the company website. Voting options include internet, mail, or in person; beneficial owners holding shares in street name must obtain a legal proxy from their broker to attend.
Cosmos Health reported record Q1 2026 revenue of $17.93 million, up 31% from $13.71 million a year earlier, driven by growth across pharmacies, branded nutraceuticals, and contract manufacturing. Despite this, margins compressed and the company posted a larger GAAP net loss of $2.81 million versus $0.82 million.
On a non-GAAP basis, Adjusted EBITDA was near breakeven at -$0.23 million, compared with positive $0.37 million in Q1 2025, and Adjusted Net Loss was $1.00 million. The balance sheet improved as total liabilities fell by $4.51 million, or 9.6%, to $42.54 million, while stockholders’ equity rose 7.6% to $19.83 million, improving the liabilities-to-assets ratio to 68.2%. Cash and cash equivalents were about $2.16 million, and management highlighted ongoing U.S. expansion and an expectation that Adjusted EBITDA will turn positive as growth investments scale.
Cosmos Health Inc. reported first‑quarter 2026 revenue of $17.9 million, up from $13.7 million a year earlier, but its net loss widened to $2.8 million, or $0.06 per share. Higher cost of goods sold and operating expenses pushed operating loss to $2.2 million, and non‑operating items, including a $442,439 loss on digital assets, further weighed on results.
Operating cash outflow was $1.1 million, partially offset by $347,627 of net cash from financing activities. Cash and cash equivalents were $514,702 and restricted cash $1.64 million as of March 31, 2026, with positive working capital of $2.8 million and stockholders’ equity of $19.8 million.
The company raised gross proceeds of about $1.83 million through its At‑the‑Market program and continued converting portions of its 2025 convertible notes into equity. Management nonetheless disclosed that recurring losses, negative operating cash flows, and reliance on external financing create “substantial doubt” about Cosmos Health’s ability to continue as a going concern over the next 12 months.
Cosmos Health Inc. filed an amendment to Schedule 13G/A reporting beneficial ownership of 4,143,007.21 shares of Common Stock, representing 8.152% of the class. The filing states this percentage is based on approximately 50,824,657 shares outstanding as of April 14, 2026. The report lists Andreas Bovopoulos as the beneficial owner with sole voting and dispositive power over the reported shares.
Cosmos Health Inc. filed an amended registration statement to register 73,523,716 shares of Common Stock for resale by selling stockholders, consisting of 67,045,455 shares potentially issuable under the August 2025 Note and the Second Note and 6,478,261 shares potentially issuable under the June 2025 Note. The registration is based on maximum potential conversion at a $0.176 conversion/floor price and assumes notes and in-kind interest remain outstanding until maturity.
As of April 23, 2026, the company reported 52,617,105 shares issued and outstanding; the prospectus shows a pro forma post-offering figure of 126,054,324 shares. The Selling Stockholders will receive proceeds from resale; the company will not receive proceeds from these sales. The prospectus also discloses the company’s recently adopted digital assets treasury strategy, including prior purchases of Ethereum and Bitcoin, custodial arrangements with BitGo Prime LLC, engagement of Prime Ledger LLC, and staking plans, and highlights substantial risks, going concern disclosures, and applicable accounting (ASU 2023-08).
Cosmos Health reported record full year 2025 revenue of $65.27 million, up 20% from 2024, driven by growth across contract manufacturing, wholesale distribution and proprietary brands. Gross profit rose to $7.90 million, an 83% increase, and gross margin expanded to 12.10% from 7.92%, reflecting a richer product mix and efficiency gains.
Despite this, the company posted a GAAP net loss of $19.14 million, wider than 2024, as operating expenses climbed to $24.60 million on hiring, global expansion and large provisions for doubtful accounts. On a non-GAAP basis, Adjusted EBITDA modestly improved to $(3.36) million, while Adjusted net loss per share improved from $(0.65) to $(0.12).
Liquidity strengthened, with cash and cash equivalents increasing to $3.46 million from $0.32 million and total assets rising to $65.48 million. The company launched a digital asset treasury strategy, including a financing facility of up to $300 million and a $2 million Ethereum investment, and secured long-term manufacturing contracts covering over 12 million units. CEO Greg Siokas increased his ownership by more than 3.3 million shares.
Cosmos Health Inc. files its annual report outlining a diversified healthcare business spanning generic drugs, proprietary nutraceuticals, biocides, medical devices and telehealth. The company operates GMP- and EMA‑certified manufacturing in Greece, wholesale distribution across Europe and the UK, and a growing Sky Premium Life nutraceutical brand.
Cosmos highlights an innovation‑focused pipeline, including CCX0722, an obesity and weight‑management hydrogel product targeted for a third or fourth quarter 2026 market launch, and several oncology programs backed by WIPO patents and exclusive licenses. It also acquired the AI‑driven Cloudscreen drug‑repurposing platform and filed multiple patent applications for neurological and hematologic indications.
The report notes 2025 inventory of $5.8 million, geographically concentrated revenues in Greece, and a workforce of 163 employees. During 2025, Cosmos used an at‑the‑market share program, equity compensation plans and debt‑for‑equity exchanges to raise capital, settle obligations and fund R&D initiatives and growth strategy.